US FDA Succession Question Looms For Biden Administration As Hahn Departure Nears
As is tradition, political appointments offer resignations when a new administration takes office. The incoming president can ask them to stay but often they are let go. Commissioner Hahn is expected to be among the many Trump administration agency heads who will depart.
You may also be interested in...
CBER Director Marks will no longer have to recuse himself from COVID-19 product reviews, a move seen as resoundingly positive by former senior FDA leaders. CDER Director Woodcock will now be free to focus solely on COVID-19 and bring her unique depth of agency experience to the Trump Administration's effort to speed development of vaccines, therapeutics and diagnostics for coronavirus.
In his first speech to an outside group, Sharpless strikes a collaborative tone, saying he expects to listen to the advice of the FDA bar, as well as his own experts.
Scott Gottlieb will formally implement a new structure for the Office of the Commissioner just days before he departs from the job. That may be odd timing, but the new structure is in many ways a perfect capstone for Gottlieb’s tenure.